| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5547930 | NOVO NORDISK INC | AspB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5840680 | NOVO NORDISK INC | ASPB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5834422 | NOVO NORDISK INC | AspB28 insulin compositions |
Sep, 2013
(10 years ago) | |
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
Novolog Mix 70/30 is owned by Novo Nordisk Inc.
Novolog Mix 70/30 contains Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant.
Novolog Mix 70/30 has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Novolog Mix 70/30 are:
- US5547930
- US5840680
- US5834422
- US5618913
- US5618913*PED
- US5866538
- US5866538*PED
Novolog Mix 70/30 was authorised for market use on 01 November, 2001.
Novolog Mix 70/30 is available in injectable;subcutaneous dosage forms.
Novolog Mix 70/30 can be used as method of treating a patient suffering from diabetes mellitus.
The generics of Novolog Mix 70/30 are possible to be released after 19 December, 2017.
Market Authorisation Date: 01 November, 2001
Treatment: Method of treating a patient suffering from diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG MIX 70/30 family patents
